Blinatumomab Side Effects
Applies to blinatumomab: intravenous powder for solution.
Important warnings
This medicine can cause some serious health issues
Intravenous route (powder for solution)
Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving blinatumomab; interrupt or discontinue blinatumomab and treat with corticosteroids as recommended.
Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving blinatumomab.
Interrupt or discontinue blinatumomab as recommended.
Precautions
It is very important that your doctor check your or your child's progress at regular visits to make sure this medicine is working properly. Blood tests are needed to check for unwanted effects.
Using this medicine while you are pregnant can harm your unborn baby. If you are a woman who can get pregnant, your doctor may do tests to make sure you are not pregnant before receiving this medicine. Use an effective form of birth control during treatment and for at least 48 hours after your treatment ends to keep from getting pregnant. If you think you have become pregnant while receiving this medicine, tell your doctor right away.
This medicine may cause cytokine release syndrome (CRS) and infusion reactions. These may be life-threatening and require immediate attention. Tell your doctor right away if you or your child have a fever, chills, headache, nausea, lightheadedness, dizziness, fainting, skin rash, trouble breathing, or tiredness or weakness.
Check with your doctor right away if you or your child have seizures, loss of balance, loss of consciousness, confusion, disorientation, difficulty with speaking, or slurred speech.
This medicine can temporarily lower the number of white blood cells in your blood, which increases your chance of getting an infection. If you can, avoid people with infections. Check with your doctor immediately if you think you or your child are getting an infection or if you have a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.
This medicine may cause a serious reaction, called tumor lysis syndrome (TLS). Your doctor may give you a medicine to help prevent this. Call your doctor right away if you or your child have a change in how much or how often you urinate, muscle or joint pain, rapid weight gain, swelling of the feet or lower legs, or unusual tiredness or weakness.
Pancreatitis may occur while you are using this medicine. Tell your doctor right away if you or your child have sudden and severe stomach pain, chills, constipation, nausea, vomiting, fever, or lightheadedness.
This medicine may make you dizzy, confused, or less alert than you are normally. Do not drive or do anything else that could be dangerous until you or your child know how this medicine affects you.
While you are being treated with blinatumomab, do not have any immunizations (vaccinations) without your doctor's approval. Live virus vaccinations should not be given for at least 2 weeks before start of treatment, during treatment, and until recovery following the last cycle of this medicine.
This medicine may contain benzyl alcohol which may cause serious reactions (eg, gasping syndrome) to newborn or premature infants. Talk to your doctor if you have concerns.
Serious side effects of blinatumomab
Along with its needed effects, blinatumomab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking blinatumomab:
More common side effects
- agitation
- bloating or swelling of the face, arms, hands, lower legs, or feet
- blurred vision
- chest pain or tightness
- chills
- confusion
- cough
- dizziness
- fever
- headache
- hoarseness
- irritability
- lower back or side pain
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- rapid, shallow breathing
- seeing, hearing, or feeling things that are not there
- seizures
- sore throat
- stiff neck
- tingling of the hands or feet
- trouble breathing
- unusual bleeding or bruising
- unusual tiredness or weakness
- unusual weight gain or loss
- vomiting
Incidence not known
- cloudy urine
- darkened urine
- discouragement
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- extremely high fever or body temperature
- eye pain
- feeling sad or empty
- general feeling of illness
- irritability
- lack or loss of strength
- loss of interest or pleasure
- mood or mental changes
- pains in the stomach, side, or abdomen, possibly radiating to the back
- persistent bleeding or oozing from puncture sites, mouth, or nose
- pounding in the ears
- problems with speech or speaking
- rash
- slow or fast heartbeat
- stomach pain
- sweating
- swelling of the hands, ankles, feet, or lower legs
- trouble sleeping
- ulcers, sores, or white spots in the mouth
- yellow eyes or skin
Other side effects of blinatumomab
Some side effects of blinatumomab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
- bone, joint, or muscle pain
- change in urination
- decreased appetite
- diarrhea
- difficulty having a bowel movement
- dry mouth
- increased hunger or thirst
- irregular heartbeat
- muscle pain or cramps
- pain in the arms or legs
- shakiness in the legs, arms, hands, or feet
For healthcare professionals
Applies to blinatumomab: intravenous powder for injection.
General adverse events
The most common adverse reactions occurring in 20% of patients or greater were pyrexia, infusion-related reactions, headache, infections (pathogen unspecified), tremor, nausea, anemia, thrombocytopenia, edema, febrile neutropenia, and chills.[Ref]
Cardiovascular
- Very common (10% or more): Arrhythmia (up to 14%), hypotension (up to 14%), tachycardia (up to 10.6%)
- Frequency not reported: Hypertension/increased blood pressure, hypotension, flushing/hot flush, capillary leak syndrome
Arrhythmia includes bradycardia, sinus arrhythmia, sinus bradycardia, sinus tachycardia, and ventricular extrasystoles.
Dermatologic
- Very common (10% or more): Rashes such as contact dermatitis, eczema, erythema, and maculopapular rash (up to 16%)
Gastrointestinal
- Very common (10% or more): Diarrhea (up to 19.7%), vomiting (up to 19%), nausea (up to 23.9%), constipation (up to 13.5%), abdominal pain (up to 10.6%)
- Postmarketing reports: Life-threatening or fatal pancreatitis (in combination with dexamethasone)
Hematologic
- Very common (10% or more): Neutropenia (up to 31%), leukopenia (up to 14%), thrombocytopenia (up to 21%), anemia (up to 25%), decreased lymphocyte count (up to 80%), decreased white blood cell count (up to 53%), decreased hemoglobin (up to 29%), decreased neutrophil count (up to 57%), decreased platelet count (up to 47%), febrile neutropenia (up to 20.4%)
- Common (1% to 10%): Leukocytosis
- Uncommon (0.1% to 1%): Lymphadenopathy, hematophagic histiocytosis
Hepatic
- Very common (10% or more): Hypertransaminasemia/elevated liver enzymes (up to 15%), increased ALT (up to 11%)
- Common (1% to 10%): Increased bilirubin, increased AST
- Frequency not reported: Hyperbilirubinemia
Hypersensitivity
- Frequency not reported: Hypersensitivity and reactions related such as anaphylaxis, angioedema, allergic dermatitis, drug eruption, drug hypersensitivity, erythema multiforme, and urticaria
Immunologic
- Very common (10% or more): Infusion-related reactions (up to 77%), decreased immunoglobulins (up to 18%), cytokine release syndrome (up to 14%)
- Common (1% to 10%): Anti-blinatumomab antibodies
Infusion-related reaction includes the term infusion-related reaction and the following events occurring with the first 48 hours of infusion lasting 2 days or less: cytokine release syndrome, eye swelling, hypertension, hypotension, myalgia, periorbital edema, pruritus generalized, pyrexia, and rash.
Decreased immunoglobulins includes decreased immunoglobulin A, immunoglobulin G, immunoglobulin M, hypogammaglobulinemia, and hypoglobulinemia.
Metabolic
- Frequency not reported: Increased alkaline phosphatase, tumor lysis syndrome
Musculoskeletal
- Very common (10% or more): Back pain (up to 12%)
- Frequency not reported: Chest pain (non-cardiac), pain in extremity, bone pain
Nervous system
- Very common (10% or more): Headache (up to 39%), tremor (up to 31%), aphasia (up to 12%), dizziness (up to 10%), encephalopathy (up to 10%)
- Frequency not reported: Immune effector cell-associated neurotoxicity syndrome (ICANS), seizures/generalized tonic-clonic seizures, speech disorder, hypoesthesia, tremor, altered state of consciousness, dizziness, memory impairment, aphasia, cognitive disorder, speech disorder, hypoesthesia, encephalopathy, paresthesia, and cranial nerve disorders
Some neurological adverse effects may represent signs/symptoms of immune effector cell-associated neurotoxicity syndrome (ICANS).
Encephalopathy includes cognitive disorder, depressed level of consciousness, disturbance in attention, lethargy, leukoencephalopathy, memory impairment, somnolence, and toxic encephalopathy.
Tremor includes essential and intention tremors.
Other
- Very common (10% or more): Pyrexia/increased body temperature (up to 91%), infections with unspecified pathogen (up to 39%), chills (up to 28%), increased weight (up to 10%), edema (up to 18%), viral infection (up to 11%), bacterial infection (up to 14%), fungal infections (up to 10%)
- Common (1% to 10%): Sepsis
- Frequency not reported: Peripheral edema, pain, medication error and overdose, hyperthermia, systemic inflammatory response syndrome
Psychiatric
- Very common (10% or more): Insomnia (up to 18%)
- Frequency not reported: Confusional state, disorientation, depression
Respiratory
- Very common (10% or more): Cough (up to 13%)
- Common (1% to 10%): Pneumonia, dyspnea, productive cough, wheezing
- Uncommon (0.1% to 1%): Exertional dyspnea, acute respiratory failure
See also:
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Mercaptopurine
Mercaptopurine systemic is used for acute lymphoblastic leukemia, autoimmune hepatitis, crohn's ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Doxorubicin
Doxorubicin systemic is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder ...
Imatinib
Imatinib is used to treat certain types of leukemia, bone marrow disorders, and skin cancer ...
Methotrexate
Methotrexate is used to treat certain types of cancer of the breast, skin, head and neck, or lung ...
References
1. (2024) "Product Information. Blincyto (blinatumomab)." Amgen USA
2. (2023) "Product Information. Blincyto (blinatumomab)." Amgen Australia Pty Ltd
3. (2024) "Product Information. Blincyto (blinatumomab)." Amgen Ltd
Frequently asked questions
- How much does Blincyto (blinatumomab) cost?
- Is Blincyto (blinatumomab) chemotherapy?
- How is Blincyto administered?
More about blinatumomab
- Check interactions
- Compare alternatives
- Reviews (2)
- Dosage information
- During pregnancy
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Blinatumomab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.